1 minute reading time (31 words)

Summit-07: A Randomized Trial of Nktr-181, a New Molecular Entity, Full Mu-Opioid Receptor Agonist for Chronic Low-Back Pain

NKTR-181, a new molecular entity, mu-opioid receptor agonist with an inherently slow rate of central nervous system (CNS) entry, was designed to provide analgesia while reducing abuse potential. Full story

Related Posts

The AAPM Annual Meeting offers education and networking opportunities for all members of the pain care team.

Learn More